(The following press release from Bayer was received by e-mail. It was not 
confirmed by the sender.) 
Dear Newsletter Subscriber, 
The following news item has been released: 
Immunotherapies against cancer:
Bayer HealthCare to broaden strategic alliance with German Cancer Research
Joint immunotherapy research laboratory at the National Center for Tumor
Diseases (NCT) in Heidelberg / Operations at the joint laboratory scheduled
to start in the middle of 2013 / Additional investments of up to €3 million
per year 
Berlin, April 10, 2013 - Bayer HealthCare (Bayer) and the German Cancer
Research Center (DKFZ) will extend their successful strategic research
alliance in search of novel cancer therapeutics by focusing their
activities also on the field of immunotherapy. Immunotherapies are a
promising approach to treat cancer with the aim to selectively reactivate
the body's own immune system so that it attacks tumor cells. 
For the first time, scientists from the German Cancer Research Center and
Bayer will work together in a joint laboratory located at the National
Center for Tumor Diseases (NCT) in Heidelberg to develop novel
immunotherapies. The joint laboratory will accommodate up to twelve staff,
and first projects are expected to start in the middle of this year. The
partners will invest together up to €3 million per year under the expanded
"We are looking forward to interlinking our collaboration with the German
Cancer Research Center more closely to develop new treatment options in the
field of immunotherapy for patients suffering from cancer", said Professor
Dr. Andreas Busch, Member of the Executive Committee of Bayer HealthCare
and Head of Global Drug Discovery. "Bayer is committed to develop
innovative therapies that can help people with serious diseases such as
cancer to live longer and improve their quality of life." 
"The German Cancer Research Center's excellent expertise in basic research
in oncology and Bayer's many years of experience in the development of new
therapeutic options complement each other perfectly. Within the next five
years, we aim to identify at least two new drug candidates in the field of
cancer immunotherapy and to jointly develop them up to the start of
clinical trials", says Professor Dr. Otmar D. Wiestler, Chairman of the
DKFZ's Management Board. 
The partners will build on established structures of their existing
collaboration including joint review processes of individual projects and
resource allocations. The rights to the research findings are shared
equally between the partners. 
"The goal of one of our joint projects is to look for immunosuppressive
molecules on the surface of tumor cells. In a next step we want to block
them with antibodies and thereby activate the specific immune response
against the tumor cells", explains Professor Dr. Philipp Beckhove, Head of
Translational Immunology at the DKFZ. "The new joint laboratory allows us
to closely and continuously collaborate with the colleagues from Bayer and,
thus, will support the faster translation of concepts from the lab into
clinical trials." 
The partners can already look back on more than four successful years of
collaborative work. Twenty-two projects have been initiated so far, and
some of these have already reached important milestones and moved on to the
next phase of drug development namely compound screening for new potential
drug candidates. Up to now, the two partners have invested more than €10
million in their ongoing joint research since end of 2008. 
About the German Cancer Research Center
The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)
with its more than 2,500 employees is the largest biomedical research
institute in Germany. At DKFZ, more than 1,000 scientists investigate how
cancer develops, identify cancer risk factors and endeavor to find new
strategies to prevent people from getting cancer. They develop novel
approaches to make tumor diagnosis more precise and treatment of cancer
patients more successful. The staff of the Cancer Information Service (KID)
offers information about the widespread disease of cancer for patients,
their families, and the general public. Jointly with Heidelberg University
Hospital, DKFZ has established the National Center for Tumor Diseases (NCT)
Heidelberg, where promising approaches from cancer research are translated
into the clinic. In the German Consortium for Translational Cancer Research
(DKTK), one of six German Centers for Health Research, DKFZ maintains
translational centers at seven university partnering sites. Combining
excellent university hospitals with high-profile research at a Helmholtz
Center is an important contribution to improving the chances of cancer
patients. DKFZ is a member of the Helmholtz Association of National
Research Centers, with ninety percent of its funding coming from the German
Federal Ministry of Education and Research and the remaining ten percent
from the State of Baden-Württemberg. 
About the National Center for Tumor Diseases Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint project
of the German Cancer Research Center (DKFZ), Heidelberg University
Hospitals, Thorax Clinic Heidelberg and German Cancer Aid (Deutsche
Krebshilfe). The aim of NCT is to link promising approaches from cancer
research with patient care from diagnosis over treatment to follow-up care
and prevention. At the heart of NCT is the interdisciplinary Tumor
Outpatient Clinic where patients benefit from an individual treatment plan
provided in a timely manner by interdisciplinary expert boards called Tumor
Boards. Participation in clinical trials provides access to innovative
therapies. Thus, NCT is a trend-setting platform for the transfer of new
research results from the laboratory to clinical practice. 
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields
of health care, agriculture and high-tech materials. Bayer HealthCare, a
subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one
of the world’s leading, innovative companies in the healthcare and medical
products industry and is based in Leverkusen, Germany. The company combines
the global activities of the Animal Health, Consumer Care, Medical Care and
Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop,
manufacture and market products that will improve human and animal health
worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec
31, 2012) and is represented in more than 100 countries. More information
Our online press service is just a click away: 
Find more information at 
Forward-Looking Statements
This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management.
Various known and unknown risks, uncertainties and other factors could lead
to material differences between the actual future results, financial
situation, development or performance of the company and the estimates
given here. These factors include those discussed in Bayer’s public reports
which are available on the Bayer website at The
company assumes no liability whatsoever to update these forward-looking
statements or to conform them to future events or developments. 
This press release is available here: 
Yours BayNews Editorial Team 
Bayer AG
Building W11
51368 Leverkusen, Germany 
Further news releases you can find here: 
N.B. This is an automatically generated e-mail which you cannot reply to.
If you have any questions, please send us an e-mail via our contact form: 
You can cancel your subscription to the BayNews-Newsletter or change your
personal settings at any time by going to 
To ensure receipt, please add to your
address book or list of trusted senders. 
© Bayer AG, 51368 Leverkusen, Germany. 
All rights reserved. The entire contents, including images, graphics,
animations etc., of this e-mail and the server are
Board of Management: Marijn Dekkers, Chairman | Werner Baumann, Michael
König, Wolfgang Plischke, Richard Pott
Chairman of the Supervisory Board: Werner Wenning
Registered office: Leverkusen | Local Court  of Cologne, HRB 48248
Press spacebar to pause and continue. Press esc to stop.